Rhythm Pharmaceuticals, Inc. July 09, 2025 - by Joey Ramson $RYTM is hitting all-time highs and leading the Prism MarketView Weight Loss index after releasing positive Phase 2 data for its obesity drug bivamelagon. Share this article:
